Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Candel Therapeutics (CADL) Assets Average (2021 - 2023)

Candel Therapeutics' Assets Average history spans 3 years, with the latest figure at $54.4 million for Q3 2023.

  • For Q3 2023, Assets Average fell 39.0% year-over-year to $54.4 million; the TTM value through Sep 2023 reached $54.4 million, down 39.0%, while the annual FY2022 figure was $83.4 million, 30.91% up from the prior year.
  • Assets Average for Q3 2023 was $54.4 million at Candel Therapeutics, down from $63.0 million in the prior quarter.
  • Across five years, Assets Average topped out at $97.4 million in Q2 2022 and bottomed at $54.4 million in Q3 2023.
  • The 3-year median for Assets Average is $81.3 million (2022), against an average of $78.8 million.
  • The largest annual shift saw Assets Average surged 40.73% in 2022 before it crashed 39.0% in 2023.
  • A 3-year view of Assets Average shows it stood at $92.6 million in 2021, then decreased by 12.13% to $81.3 million in 2022, then plummeted by 33.15% to $54.4 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Assets Average are $54.4 million (Q3 2023), $63.0 million (Q2 2023), and $72.5 million (Q1 2023).